c-Met/HGFR
Os inibidores de c-Met/HGFR visam o Receptor do Fator de Crescimento de Hepatócitos (c-Met), uma tirosina quinase envolvida em processos celulares como crescimento, motilidade e morfogênese. A sinalização de c-Met está implicada na progressão do câncer, na metástase e na resistência às terapias. Inibir o c-Met pode interromper o crescimento e a disseminação do tumor, tornando esses inibidores valiosos na pesquisa sobre o câncer. Na CymitQuimica, oferecemos inibidores de c-Met/HGFR para apoiar sua pesquisa em oncologia, metástase e terapias contra o câncer.
Foram encontrados 128 produtos de "c-Met/HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Crizotinib
CAS:<p>Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.</p>Fórmula:C21H22Cl2FN5OPureza:99% - 99.87%Cor e Forma:SolidPeso molecular:450.34AMG-208
CAS:<p>AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.</p>Fórmula:C22H17N5O2Pureza:98.56%Cor e Forma:SolidPeso molecular:383.4S49076
CAS:<p>S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.</p>Fórmula:C22H22N4O4SPureza:95.35% - 97.4%Cor e Forma:SolidPeso molecular:438.5DS-1205
CAS:<p>DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.</p>Fórmula:C41H42FN5O7Pureza:99.75%Cor e Forma:SolidPeso molecular:735.8Capmatinib 2HCl
CAS:<p>Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.</p>Fórmula:C23H19Cl2FN6OPureza:98.80%Cor e Forma:SolidPeso molecular:485.34SGX-523
CAS:<p>SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.</p>Fórmula:C18H13N7SPureza:99% - >99.99%Cor e Forma:SolidPeso molecular:359.41BMS-794833
CAS:<p>BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.</p>Fórmula:C23H15ClF2N4O3Pureza:98% - 99.69%Cor e Forma:SolidPeso molecular:468.84XL092
CAS:<p>XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.</p>Fórmula:C29H25FN4O5Pureza:98.60%Cor e Forma:SolidPeso molecular:528.53SCR-1481B1
CAS:<p>SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor</p>Fórmula:C32H40ClF2N6O13PPureza:98.07%Cor e Forma:SolidPeso molecular:821.12Amuvatinib
CAS:<p>Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.</p>Fórmula:C23H21N5O3SPureza:99.38% - >99.99%Cor e Forma:SolidPeso molecular:447.51PHA-665752
CAS:<p>PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.</p>Fórmula:C32H34Cl2N4O4SPureza:97.05% - 98.82%Cor e Forma:SolidPeso molecular:641.61Capmatinib
CAS:<p>Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>Fórmula:C23H17FN6OPureza:99.24%Cor e Forma:SolidPeso molecular:412.42PF-04217903
CAS:<p>MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.</p>Fórmula:C19H16N8OPureza:98.41% - 98.55%Cor e Forma:SolidPeso molecular:372.38SAR125884 hydrochlorid (1116743-46-4(free base))
CAS:<p>SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).</p>Fórmula:C25H23FN8O2S2·HClPureza:97.95%Cor e Forma:SolidPeso molecular:587JNJ-38877605
CAS:<p>JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.</p>Fórmula:C19H13F2N7Pureza:97.04% - 98.27%Cor e Forma:SolidPeso molecular:377.35Merestinib
CAS:<p>Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.</p>Fórmula:C30H22F2N6O3Pureza:95% - 99.71%Cor e Forma:SolidPeso molecular:552.53MGCD-265 analog
CAS:<p>Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.</p>Fórmula:C26H20FN5O2S2Pureza:98.06% - 98.68%Cor e Forma:SolidPeso molecular:517.6Savolitinib
CAS:<p>Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).</p>Fórmula:C17H15N9Pureza:98.12%Cor e Forma:SolidPeso molecular:345.36Capmatinib xHCl
CAS:<p>Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50</p>Fórmula:C23H18ClFN6OPureza:98.62% - 99.81%Cor e Forma:SolidPeso molecular:448.89SRI 31215 TFA
CAS:<p>SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.</p>Fórmula:C27H34F3N5O3Pureza:98.25% - 99.97%Cor e Forma:SolidPeso molecular:533.6Cabozantinib
CAS:<p>Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).</p>Fórmula:C28H24FN3O5Pureza:99.68% - 99.88%Cor e Forma:SolidPeso molecular:501.51(Z)-Semaxinib
CAS:<p>(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for</p>Fórmula:C15H14N2OPureza:98.82% - ≥95%Cor e Forma:SolidPeso molecular:238.28Cabozantinib hydrochloride
CAS:<p>Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6</p>Fórmula:C28H25ClFN3O5Pureza:99.97%Cor e Forma:SolidPeso molecular:537.96BAY-474
CAS:<p>BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe</p>Fórmula:C17H15N5Pureza:98.98%Cor e Forma:SolidPeso molecular:289.33Afatinib
CAS:<p>Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.</p>Fórmula:C24H25ClFN5O3Pureza:98.56% - 99.9%Cor e Forma:Off-White SolidPeso molecular:485.94Amivantamab
CAS:<p>Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.</p>Pureza:97.24% (SEC-HPLC) - 99.74%Cor e Forma:LiquidPeso molecular:145.88 kDaFiclatuzumab
CAS:<p>Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.</p>Pureza:95%Cor e Forma:LiquidDavutamig
CAS:<p>Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.</p>Pureza:98%Cor e Forma:LiquidBafisontamab
CAS:<p>Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].</p>Cor e Forma:LiquidMAPK-IN-2
<p>MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell</p>Fórmula:C20H11Cl2N3OPureza:98%Cor e Forma:SolidPeso molecular:380.23SU11274
CAS:<p>SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.</p>Fórmula:C28H30ClN5O4SPureza:98.62% - 99.53%Cor e Forma:Orange PowderPeso molecular:568.09AMG-458
CAS:<p>AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.</p>Fórmula:C30H29N5O5Pureza:99.91% - 99.98%Cor e Forma:SolidPeso molecular:539.58Glesatinib
CAS:<p>Glesatinib is an orally active and potent dual inhibitor of MET/SMO.</p>Fórmula:C31H27F2N5O3S2Pureza:98%Cor e Forma:SolidPeso molecular:619.7Dalmelitinib
CAS:<p>Dalmelitinib: oral c-Met kinase inhibitor, IC50 2.9 nM, disrupts MET, AKT, ERK in cancer cells, for NSCLC research.</p>Fórmula:C22H16FN7O2SCor e Forma:SolidPeso molecular:461.47c-Met-IN-16
CAS:<p>c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research .</p>Fórmula:C21H17F2N9OCor e Forma:SolidPeso molecular:449.42ABN401
CAS:<p>ABN401: potent c-MET inhibitor (IC50: 10 nM), cytotoxic to MET-dependent cancers, blocks tumor c-MET phosphorylation, for cancer research.</p>Fórmula:C29H34N12OCor e Forma:SolidPeso molecular:566.66AC-386
CAS:<p>AC-386, a potent c-Met inhibitor (IC50 7.42 nM), inhibits cancer cell growth and aids anti-cancer resistance study.</p>Fórmula:C35H34FN5O6Cor e Forma:SolidPeso molecular:639.67Tyrosine kinase-IN-4
CAS:<p>Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor [1].</p>Fórmula:C23H21N3O3Cor e Forma:SolidPeso molecular:387.43LCRF-0004
CAS:<p>LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.</p>Fórmula:C28H18F4N6O2SCor e Forma:SolidPeso molecular:578.54c-Met-IN-13
CAS:<p>c-Met-IN-13: potent c-Met inhibitor (IC50 2.43 nM), exhibits anti-proliferative, cytotoxic effects; potential cancer therapy.</p>Fórmula:C30H28F2N2O6Cor e Forma:SolidPeso molecular:550.55SAR125844
CAS:<p>SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)</p>Fórmula:C25H23FN8O2S2Pureza:98.73%Cor e Forma:SolidPeso molecular:550.63c-Met-IN-11
CAS:<p>c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).</p>Fórmula:C30H20F2N4O3Cor e Forma:SolidPeso molecular:522.5Glesatinib hydrochloride
CAS:<p>Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.</p>Fórmula:C31H28ClF2N5O3S2Pureza:98%Cor e Forma:SolidPeso molecular:656.16Axl-IN-8
CAS:<p>Axl-IN-8 (NO.1) is a potent inhibitor of AXL (IC50<1 nM) and also inhibits c-MET (IC50: 1-10 nM). : 120.3 nM).</p>Fórmula:C31H29FN6O3Cor e Forma:SolidPeso molecular:552.6T-1840383
CAS:<p>T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.</p>Fórmula:C30H25ClFN5O4Cor e Forma:SolidPeso molecular:574MK-8033 hydrochloride
CAS:<p>MK-8033 hydrochloride is an oral ATP-competitive c-Met/Ron inhibitor (IC50: c-Met 1nM, Ron 7nM), used for various cancers including NSCLC.</p>Fórmula:C25H22ClN5O3SCor e Forma:SolidPeso molecular:507.99Mifanertinib dimaleate
CAS:<p>Mifanertinib dimaleate is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Fórmula:C29H27ClF3N5O10Cor e Forma:SolidPeso molecular:698c-Met-IN-12
CAS:<p>c-Met-IN-12: potent c-Met/AXL/Mer/TYRO3 inhibitor, IC50=10.6 nM, oral, anti-tumor, scaffold for selectivity enhancement.</p>Fórmula:C34H29FN4O4Cor e Forma:SolidPeso molecular:576.62Boditrectinib
CAS:<p>Boditrectinib: potent TKI, anti-cancer, researches cancer, inflammation, neurodegeneration, infections.</p>Fórmula:C23H24F2N6OCor e Forma:SolidPeso molecular:438.47Mifanertinib
CAS:<p>Mifanertinib is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Fórmula:C21H19ClF3N5O2Cor e Forma:SolidPeso molecular:465.86
